The content on this site is intended for healthcare professionals only
Dr Satoru Miura speaks to ecancer about the UpSwinG study.
It is a real-world, non-interventional cohort study on TKI activity in patients with EGFR mutation-positive (EGFRm ) NSCLC with uncommon mutations. Initially, he explains the background of the study.
Dr Miura then mentions the methodology of the UpSwinG study.
He also discusses the results and future impact of this study. EGFR TKIs were the preferred tx option in patients with uncommon EGFR mutations.
Dr Miura mentions that response was highest in patients with major rare compound mutations.
Data were in line with recent analyses of afatinib in rare mutations.
The study concludes that Tx with an EGFR TKI should be considered as standard for patients with uncommon mutations, although many ex20ins were not responsive.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
ESMO 2023: Latest in EGFR Ex20ins advanced NSCLC
Amivantamab shows robust efficacy in post-platinum therapy patients with EGFR Ex20ins NSCLC
